EUDAMED 2026: Is Med-Tech Ready for Full MDR Enforcement?

Under the European Medical Device Regulation (MDR), regulatory expectations in the European medical device market have shifted from fragmented, country-level oversight to a far more connected, transparent system. At the center of this transformation is EUDAMED, the European Database on Medical Devices, which is rapidly moving toward mandatory enforcement.

For many medical device manufacturers, the conversation has already shifted from awareness to execution and, increasingly, to remediation. As EUDAMED modules continue to roll out and scrutiny intensifies under MDR and IVDR, organizations in late-stage preparation are confronting a more complex reality: EUDAMED is not just a submission portal, but a live regulatory environment that exposes data inconsistencies, process gaps and system limitations.

With mandatory use of four modules beginning on May 28, 2026, this article examines the current state of medical device industry readiness for compliance with EUDAMED. We’ll look at what has changed, where manufacturers are struggling and how to operationalize EUDAMED readiness with the right systems in place.

Contents

What is EUDAMED?

Key EUDAMED requirements for manufacturers

Where EUDAMED stands now

Where regulators are paying closer attention

EUDAMED readiness gaps manufacturers are encountering 

How to close the final gaps before full enforcement 

QT9 QMS enables EUDAMED execution at scale

Looking ahead: Increasing enforcement and visibility

What is EUDAMED?

EUDAMED is a centralized database mandated under EU MDR that is designed to improve transparency, traceability and coordination across the medical device lifecycle. It serves as a single source of regulatory data that historically was located across national databases, notified bodies and manufacturer sources.

Rather than relying on siloed systems, EUDAMED consolidates regulatory data into six compliance avenues:

• Actor registration
• UDI/device registration
• Notified Bodies and certificates
• Clinical investigations and performance studies
• Vigilance and post-market surveillance
• Market surveillance

Each of the above modules supports a different aspect of compliance, but together they create a comprehensive, real-time view of device safety and performance across the EU.

For manufacturers, this means increased visibility and increased responsibility for maintaining accurate, up-to-date data. 

Key EUDAMED requirements for manufacturers

EUDAMED registration requires structured processes, clean data and cross-functional coordination.

Actor registration and SRN

Manufacturers must register as economic operators and obtain a Single Registration Number (SRN). This serves as the primary identifier across all of EUDAMED. While some modules have transition periods, actor registration becomes mandatory on May 28. 

UDI and device data submission

Devices must be registered with complete Unique Device Identifier (UDI) information, including:

• Basic UDI-DI
• Device classification
• Risk class and intended use
• Labeling and packaging details

This data must be consistent across technical documentation, labeling and internal systems. MDR/IVDR devices coming to market on or after May 28 must be registered. For legacy devices placed on the market before May 28, there is a six-month transition period before mandatory use. 

Clinical and performance data

Manufacturers are responsible for submitting data on clinical investigations and performance studies, where applicable. This aligns with MDR’s stronger emphasis on clinical evidence.

Vigilance and post-market surveillance

EUDAMED centralizes incident reporting, field safety corrective actions and trend reporting. Manufacturers must ensure:

• Timely submission of serious incidents
• Ongoing PMS data collection
• Alignment between complaint handling and vigilance reporting

Certificate and Notified Body data

All certificates issued by Notified Bodies are recorded in EUDAMED, requiring alignment between manufacturer documentation and notified body submissions. 

Where EUDAMED stands now

Four EUDAMED modules become mandatory on May 28, 2026:

• Actor registration – Economic operators must be registered as actors (this includes Authorized Representatives)
• UDI/device registration – Devices coming to market on or after May 28 must be registered in the UDI/Devices module. There is a six-month transition period for legacy devices.
• Notified Bodies and certificates – NBs must upload MDR/IVDR certificates
• Marketing surveillance – market surveillance will be coordinated through EUDAMED

The remaining modules – Clinical Investigations and Vigilance – will be phased in. The European Commission has said that EUDAMED will become fully mandatory once all modules are declared functional and following a complete transition period.

Already, though, Competent Authorities (supervising entities) are increasingly using EUDAMED data to:

• Cross-check technical documentation
• Validate UDI consistency
• Monitor certificate status and scope
• Identify gaps in post-market surveillance

For manufacturers, this means that EUDAMED entries are being actively audited against your QMS and technical files.

Where regulators are paying closer attention

As EUDAMED usage grows, several focus areas have emerged where manufacturers are being scrutinized more closely.

UDI consistency across systems

Regulators are comparing Unique Device Identified (UDI) data submitted in EUDAMED with:

• Device labeling
• GUDID (for global manufacturers)
• Technical documentation

Even minor discrepancies, such as naming conventions or packaging hierarchies, can trigger further investigation.

Certificate alignment

Notified Body (NB) certificate data uploaded into EUDAMED must match:

• Device listings
• Scope of certification
• Expiration and renewal timelines

Any mismatch between manufacturer records and Notified Body submissions creates visibility issues.

Vigilance readiness

Although not all vigilance functionality is fully mandatory, regulators expect manufacturers to demonstrate readiness by:

• Structuring complaint data for rapid reporting
• Ensuring traceability from incident to corrective action
• Aligning PMS plans with EUDAMED reporting expectations

Actor and role accuracy

Incorrect or outdated actor registrations, including authorized representatives and importers, are becoming a common finding during audits.

EUDAMED readiness gaps manufacturers are encountering

Even organizations that are close to MDR compliance for EUDAMED are still encountering friction in several areas.

Data normalization issues

In addition to data often being located across several unconnected systems, internal departments often use slightly different naming conventions, formats or identifiers. Consolidating data into a consistent format that meets EUDAMED standards requires extensive internal coordination.

Data reconciliation

Teams with disconnected systems are spending significant time preparing data for entry into EUDAMED. Manufacturers with large device portfolios may need to prepare hundreds or even thousands of device records, each requiring validation before submission.

XML bulk uploads offer a more scalable alternative, but they introduce their own complexity. Each submission must strictly conform to EUDAMED’s XSD schemas, and even a single formatting error can result in the rejection of an entire batch.

For many organizations, this level of data preparation exceeds the capabilities of internal systems and teams, making data consistency and validation one of the most pressing challenges in EUDAMED readiness.

Internal alignment

Regulatory teams are often ready before quality and operations teams are fully aligned, creating bottlenecks in submission and updates.

How to close the final gaps before full enforcement

For manufacturers currently preparing EUDAMED registrations, the focus should shift now from building processes to stress-testing them.

Establish a single source of truth

If your organization cannot confidently answer “which system owns this data,” EUDAMED readiness is at risk.

A centralized QMS should govern:

• Device master data
• UDI attributes
• Complaint and vigilance records
• CAPA and risk management

Perform data reconciliation audits

• Cross-check UDI data across all systems
• Validate certificate scope alignment
• Ensure consistency between labeling and database entries

This should be treated as a formal audit activity, not an informal review.

Simulate vigilance reporting

Run mock scenarios to test:

• Incident detection to reporting timelines
• Data availability for EUDAMED fields
• Cross-functional communication

Strengthen document governance

EUDAMED increases the importance of document accuracy and version control. Ensure:

• Technical documentation aligns with submitted data
• Change control processes are enforced
• Audit trails are complete and accessible

Prepare for continuous updates

EUDAMED is not a one-time submission. Manufacturers must maintain ongoing data accuracy as devices are updated, certificates change and PMS data evolves.

QT9 QMS enables EUDAMED execution at scale 

At this stage of EUDAMED readiness, compliance challenges are less about understanding regulations and more about operationalizing them. QT9 QMS is designed to address this phase, giving users:

Unified data architecture

QT9 centralizes quality, regulatory and operational data across 28+ modules, creating a single, consistent data environment.

This supports EUDAMED compliance by ensuring that:

• UDI data is consistent across records
• Complaint and vigilance data are linked
• CAPA actions are traceable to device issues

Real-time traceability

EUDAMED requires manufacturers to demonstrate connections between data points. QT9 automates:

• End-to-end traceability from complaint to corrective action
• Integrated risk management and document control
• Immediate access to audit-ready records

Regulatory alignment

QT9 supports key compliance requirements, including ISO 13485, and operates within an ISO 27001-certified environment. This ensures that data integrity and security expectations are met across jurisdictions.

Scalable across product portfolios and sites

With multi-site capabilities and modular format, QT9 allows manufacturers to standardize processes across regions while maintaining local compliance requirements.

Reduced reliance on manual processes

Built-in automation within QT9 QMS reduces the need for manual reconciliation by:

• Standardizing workflows
• Enforcing data consistency
• Triggering required actions and reviews

Continuous system evolution

Regulatory expectations around EUDAMED continue to evolve. QT9’s regular system upgrades and unlimited support help manufacturers stay aligned without rebuilding their infrastructure.

Looking ahead: increasing enforcement and visibility

As EUDAMED moves toward full functionality, several trends are expected:

• Greater reliance on EUDAMED data during audits
• Increased cross-border regulatory coordination
• More proactive market surveillance based on real-time data

As visibility increases, so does the expectation that manufacturers maintain accurate, connected and continuously updated data. Organizations that invest in scalable systems and data integrity will be better positioned to adapt as enforcement expands. The difference will come down to execution and whether your infrastructure can support the level of transparency EUDAMED demands.